XML 56 R42.htm IDEA: XBRL DOCUMENT v3.6.0.2
AVAILABLE-FOR-SALE SECURITIES AND FAIR VALUE MEASUREMENTS - Available-for Sale Securities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Available-for Sale Securities      
Amortized Cost $ 148,812 $ 176,778  
Gross Unrealized Gains 1 0  
Gross Unrealized Losses 0 (2)  
Estimated Fair Value 148,813 176,776  
Proceeds from sale of available-for-sale securities $ 2,995 108,077 $ 7,211
Maturity period for marketable securities      
Maximum contractual maturity period 1 year    
Average duration 1 month    
Theravance Biopharma      
Available-for Sale Securities      
Gain on sale   1,200  
Recognized losses     $ 3,800
Issuer of available-for-securities other than Theravance Biopharma      
Available-for Sale Securities      
Proceeds from sale of available-for-sale securities   100,400  
Cash and cash equivalents      
Available-for Sale Securities      
Estimated Fair Value $ 116,396 148,673  
Short-term marketable securities      
Available-for Sale Securities      
Estimated Fair Value 32,417 28,103  
U.S. government agencies      
Available-for Sale Securities      
Amortized Cost 12,428 14,406  
Gross Unrealized Gains 1 0  
Gross Unrealized Losses 0 (1)  
Estimated Fair Value 12,429 14,405  
U.S. corporate notes      
Available-for Sale Securities      
Amortized Cost   2,702  
Gross Unrealized Gains   0  
Gross Unrealized Losses   (1)  
Estimated Fair Value   2,701  
U.S. commercial paper      
Available-for Sale Securities      
Amortized Cost 72,065 10,997  
Gross Unrealized Gains 0 0  
Gross Unrealized Losses 0 0  
Estimated Fair Value 72,065 10,997  
Money market funds      
Available-for Sale Securities      
Amortized Cost 64,319 148,673  
Gross Unrealized Gains 0 0  
Gross Unrealized Losses 0 0  
Estimated Fair Value $ 64,319 $ 148,673